Company will invest approximately ¥16 billion to increase production capacity by approximately 70% to ensure a stable supply
The WAVEsystem with the WAVEcontrol 4.0 embedded
The company is focused on therapies such as skinceuticals, gastroenterology, neuropsychiatry, cardiac diabetes care etc.
Advancing to IND-enabling studies with multiple drug candidates
Supports development and commercialization of complex oral drugs using sensitive molecules, including biologicals
Syngene's collaboration with Zoetis started in 2011
Athos will perform multi-omic molecular and genetic analyses using biopsies from archived and de-identified Lahey IBD patient samples
Granite Bio's lead candidate is a novel monoclonal antibody for treatment of autoimmune and certain cancer indications. B
The addition of Sitaglyn and Siglyn to our diabetes portfolio will give patients access to a world-class oral therapy to help people manage their diabetes
These medicines have low risk of hypoglycemia, provide beta cell protection, offer cardio-renal benefits and are safe for patients with kidney or liver conditions and senior citizens
Subscribe To Our Newsletter & Stay Updated
